KaydedilenlerDerginizi ekleyin

Dergiler / BEYOGLU EYE JOURNAL / 2020 / Cilt: 5 - Sayı: 1

Outcomes of a Dispersive Ophthalmic Viscosurgical Device

Banu ACAR
Işıl Merve TORUN
Suphi ACAR
Sayfa
12–16
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, comparative studies with other OVDs are necessary.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The aim of this study was to evaluate clinical outcomes related to the protection of corneal endothelial cells and the safety of the Bio-Hyalur CS (Biotech Healthcare Group, Luzern, Switzerland) ophthalmic viscosurgical device (OVD) in routine cataract surgery.
📊
Temel Bulgular & Veri:Methods: Patients who had undergone cataract surgery using Bio-Hyalur CS as an OVD and who had at least 3 months of follow-up data were included in the study.
💡
Sonuç & Katkı:However, comparative studies with other OVDs are necessary.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: The aim of this study was to evaluate clinical outcomes related to the protection of corneal endothelial cells and the safety of the Bio-Hyalur CS (Biotech Healthcare Group, Luzern, Switzerland) ophthalmic viscosurgical device (OVD) in routine cataract surgery. Methods: Patients who had undergone cataract surgery using Bio-Hyalur CS as an OVD and who had at least 3 months of follow-up data were included in the study. Endothelial cell density (ECD) and morphology (hexagonality, area, and coefficient of variation in cell size) as well as intraocular pressure were evaluated during 3 months of follow-up. Intraoperative and postoperative complications were recorded. Results: Sixty eyes of 44 patients were included in the study. The mean preoperative ECD was 2383.5±288.67 cells/ mm2 . The mean postoperative ECD was 2186.0±359.65 cells/mm2 and 2149.7±354.49 cells/mm2 at 1- and 3-month visits, respectively. The mean coefficient of variation in cell size was 29.1±5.04% and 30.9±5.79% at preoperative and postoperative 3-month visits, respectively. The mean cell area was 426.1±52.59 µm2 and 476.6±122.26 µm2 at preoperative and postoperative 3-month visits, respectively. No adverse events were reported during the study period. Conclusion: Bio-Hyalur CS provided good endothelial protection and has a favorable safety profile. However, comparative studies with other OVDs are necessary.

🔖

Bu Makaleye Atıf Yap

ACAR, B., TORUN, I. M., ACAR, S. (2020). Outcomes of a Dispersive Ophthalmic Viscosurgical Device. BEYOGLU EYE JOURNAL, Cilt: 5 - Sayı: 1, 12–16. https://ajindex.com/articles/143171

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Anger C, Lally JM. Acanthamoeba: A review of its potential to cause keratitis, current lens solution disinfection standards and methodologies and strategies to reduce patient risk. Eye Contact Lens 2008
  2. 247–53. 2. Visvesvara GS. Free-living pathogenic amoeba. In: Lennette EH, Balows A, Hausler WJ Jr, editors. Manual of Clinical Microbiology. 3rd ed. Washington, DC: American Society of Microbiology 1980. p. 704–8. 3. Naginton J, Watson PG, Playfair TJ, McGill J, Jones BR, Steele AD. Amoebic infection of the eye. Lancet 1974
  3. 1537–40. 4. Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: Diagnosis and treatment update 2009. Am J Ophthalmol 2009
  4. 487– 99.e2. 5. Radford CF, Bacon AS, Dart JK, Minassian DC. Risk factors for acanthamoeba keratitis in contact lens users: A case-control study. BMJ 1995
  5. 1567–70. 6. Schaumberg DA, Snow KK, Dana MR. The epidemic of Acanthamoebakeratitis:Where do we stand? Cornea 1998
  6. 3–10. 7. Farhat B, Sutphin JE. Deep anterior lamellar keratoplasty for acanthamoeba keratitis complicating the use of Boston scleral lens. Eye Contact Lens 2014
  7. e5–7. 8. Yamazaki N, Kobayashi A, Yokogawa H, Ishibashi Y, Oikawa Y, Tokoro M, et al. In Vivo Imaging of Radial Keratoneuritis in Patients with Acanthamoeba keratitis by Anterior-Segment Optical Coherence Tomography. Ophthalmology 2014
  8. 2153–8. 9. Pullum KW, Whiting MA, Buckley RJ. Scleral contact lenses: The expanding role. Cornea. 2005
  9. 269–77. 10. Segal O, Barkana Y, Hourovitz D, Behrman S, Kamun Y, Avni I, et al. Scleral contact lenses may help where other modalities fail. Cornea 2003
  10. 308–10. 11. Romero-Rangel T, Stavrou P, Cotter J, Rosenthal P, Baltatzis S, Foster CS. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000
  11. 25–32. 12. Fleiszig SM, Evans DJ. Pathogenesis of contact lens-associated microbial keratitis. Optom Vis Sci 2010
  12. 225–32. 13. Zimmerman AB, Marks A. Microbial keratitis secondary to unintended poor compliance with scleral gas-permeable contact lenses. Eye Contact Lens 2014
  13. e1–4. 14. Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007
  14. 1195–9. 15. Rosenthal P, Cotter JM, Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol 2000
  15. 33–41. 16. Baran I, Bradley JA, Alipour F, Rosenthal P, Le HG, Jacobs DS. PROSE